

10/081785

IFN Cofc

PATENT
674543-2001.4



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Brian Robert WALKER
U.S. Patent No. : 6,838,253
For : REGULATION OF INTRACELLULAR GLUCOCORTICOID
CONCENTRATIONS
Issued : January 4, 2005
Examiner : Stephen Glucker
Art Unit : 1647

745 Fifth Avenue
New York, NY 10151

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: **Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 27, 2005.**

Angela M. Collison, Reg. No. 51.107

(Name of Applicant, Assignee or Registered Representative)

Angela M. Collison

Signature

April 29, 2005

Date of Signature

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

IN THE SPECIFICATION:

Column 1, line 42 should read: --concentrations of cortisol in the **liver** substantially reduce—

IN THE ABSTRACT:

Please replace the Abstract in its entirety. The abstract should read as follows:

--This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects, which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.—

REMARKS

The typographical error in the specification and the error in the Abstract originated in the printing of the patent; these errors did not arise due to any fault of the Applicants. On February 22, 2002 Applicants submitted a Preliminary Amendment requesting that the Abstract as filed with the application be replaced with the Abstract attached to the Preliminary Amendment. Enclosed is a copy of the Preliminary Amendment as filed on February 22, 2002 along with a copy of the stamped return postcard.

It is respectfully submitted that the requested changes do not constitute new matter and this application does not require re-examination. A completed Form PTO 1050 is enclosed.

Since the errors to be corrected did not originate from the Applicants, no fee is deemed necessary; however, the Commissioner is authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Thomas J. Kowalski by Angela M. Collison
Thomas J. Kowalski
Reg. No. 32,147

Angela M. Collison
Reg. No. 51,107
(212) 588-0800

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,838,253
DATED : January 4, 2005
INVENTOR(S) : Brian Robert Walker
Christopher Richard Watkin Edwards
Jonathan Robert Seckl

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, line 42, "lever" –liver--;

(57) ABSTRACT. Please replace the Abstract in its entirety with:

--This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of inactive to the active form may be controlled, and to useful therapeutic effects, which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans. --

MAILING ADDRESS OF SENDER:
Thomas J. Kowalski, Esq.
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, New York 10151

PATENT NO. 6,838,253
No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1 and 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing, and submitting the complete provisional application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

00273196



PATENT
674543-2001.4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : WALKER et al.
Serial No. : To Be Assigned
For : REGULATION OF INTRACELLULAR
GLUCOCORTICOID CONCENTRATIONS
Filed : Concurrently Herewith
Examiner : To Be Assigned
Art Unit : To Be Assigned


745 Fifth Avenue, New York, NY 10151


EXPRESS MAIL

Mailing Label Number: EV 001580893 US

Date of Deposit: February 22, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.


(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231
Box Patent Application

Dear Sir:

Prior to examination, please amend the above-referenced application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE SPECIFICATION:

Page 1, before the first paragraph, please insert thereat:

--REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of allowed U.S. Application Serial No. 09/029,535, filed February 27, 1998, which is the National Stage application of international application PCT/GB96/02134 filed August 28, 1996, published as WO 97/07789 on March 6, 1997, and claims priority from British Application 9517622.8 filed August 29, 1995. Reference is made to U.S. Application Serial No. 10/061,044 filed January 30, 2002 as a divisional of U.S. Application Serial No. 09/029,535. Reference is also made to four additional applications, also filed as divisional applications of U.S. Application Serial No. 09/029,535 on February 22, 2002, application numbers to be assigned, (Attorney docket numbers 674543-2001.2, 674543-2001.3, 674543-2001.5 and 674543-2001.6).

The above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference.--

IN THE CLAIMS:

Kindly cancel claims 1-13, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

Kindly add new claims 14 and 15, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

--14. (New) A method for determining whether a compound or composition is a regulator of intracellular glucocorticoid activity in adipose tissue comprising determining whether said compound or composition inhibits reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in said tissue.

15. (New) The method of claim 1, wherein determining whether said compound or composition inhibits reductase activity of 11-Beta HSD1 comprises:

obtaining reductase activity of 11-Beta HSD1 in an isolate *in vitro*

adipocyte cell population, and

contacting said compound or composition with said adipocyte cell population.--

IN THE ABSTRACT:

Please accept the enclosed page entitled "Abstract".

REMARKS


The amendments made herein serve to place the application in better form for prosecution by including the lineage of the application as well as by meeting the requirement for inclusion of an abstract on a separate sheet.

No new matter is added. The amendments to the claims find support throughout the specification.

An early and favorable examination on the merits is respectfully requested.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:


Thomas J. Kowalski
Reg. No. 32,147
(212) 588-0800

ABSTRACT

This invention relates to the interconversion of inactive 11-keto steroids with their active 11B-hydroxy equivalents, to methods by which the conversion of the inactive to the active form may be controlled, and to useful therapeutic effects which may be obtained as a result of such control. More specifically, but not exclusively, the invention is concerned with interconversion between cortisone and cortisol in humans.

Mailed by express mail label EV001580893US on 2/22/02.

Serial No. TBA File No. 674543-2001.4 By TJKlamm
Title In the Matter of the Application of Walker et al.
The following due 2/22/02 in the U.S. Patent Office, was received in the Patent Office

<input type="checkbox"/> Affidavit	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Express Mail Mailing Certificate
<input type="checkbox"/> Amendment		<input type="checkbox"/> (separate sheet)
<input checked="" type="checkbox"/> Preliminary Amendment		<input checked="" type="checkbox"/> Check No. <u>020017</u> for \$ <u>370.00</u>
<input type="checkbox"/> Amendment After Final Rejection		<input type="checkbox"/> Deposit Account Order Form
<input type="checkbox"/> Request for Extension of Time		<input checked="" type="checkbox"/> Drawing <u>3</u> Sheet(s)
<input type="checkbox"/> Provisional Patent Application		<input type="checkbox"/> Information Disclosure Statement
<input checked="" type="checkbox"/> Application for Patent, including <u>(27 pages)</u>		<input type="checkbox"/> PTO Form 1449
<u>25</u> Pages Specification <u>13</u> Claims <u>total</u>		<input type="checkbox"/> Issue Fee Transmittal
<input checked="" type="checkbox"/> Declaration w/ Associate POA		<input type="checkbox"/> Brief <input type="checkbox"/> Letter
<input type="checkbox"/> Request for Filing Continuation or Divisional Application _____ sheets, in duplicate		<input type="checkbox"/> Application for TM Registration Including _____ Specimens
<input type="checkbox"/> File Wrapper Continuation Patent Application _____ sheets, in duplicate		<input type="checkbox"/> Status Request <input type="checkbox"/> Notice of Appeal
<input type="checkbox"/> PCT Request _____ sheets, including		<input type="checkbox"/> Petition <input type="checkbox"/> Response
<input type="checkbox"/> Transmittal Letter to the US/RO		<input type="checkbox"/> Priority Document
<input type="checkbox"/> Assignment <input type="checkbox"/> Recordation Cover Sheet		<input type="checkbox"/> Small Entity Declaration
		<input checked="" type="checkbox"/> Utility Patent Application Transm.
		<input checked="" type="checkbox"/> Fee transmitted

BEST AVAILABLE COPY




FROMMER, LAWRENCE
& HAUG, LLP

FROMMER LAWRENCE & HAUG, LLP
745 FIFTH AVENUE
NEW YORK, NEW YORK 10151

DOCKETED

30



© 2000 USPS recycled

BEST AVAILABLE COPY